

Paola Dongiovanni

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9261226/paola-dongiovanni-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

151
papers

7,976
citations

50
h-index

85
g-index

183
ext. papers

9,767
ext. citations

5.7
avg, IF

5.93
L-index

#	Paper	IF	Citations
151	PSD3 downregulation confers protection against fatty liver disease.. <i>Nature Metabolism</i> , 2022 , 4, 60-75	14.6	1
150	Impact of Sarcopenia and Myosteatosi s in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies.. <i>Biomedicines</i> , 2022 , 10,	4.8	1
149	Variants in PCSK7, PNPLA3 and TM6SF2 are risk factors for the development of cirrhosis in hereditary haemochromatosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 830-843	6.1	2
148	TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in InVitro Models. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021 ,	7.9	6
147	MAFLD definition underestimates the risk to develop HCC in genetically predisposed patients. <i>Journal of Internal Medicine</i> , 2021 ,	10.8	3
146	Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2021 ,	6	3
145	Adipocyte PHLPP2 inhibition prevents obesity-induced fatty liver. <i>Nature Communications</i> , 2021 , 12, 1822	17.4	3
144	Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13519	4.6	13
143	The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation. <i>EBioMedicine</i> , 2021 , 65, 103249	8.8	1
142	Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending?. <i>Metabolism: Clinical and Experimental</i> , 2021 , 117, 154708	12.7	19
141	The rs599839 A>G Variant Disentangles Cardiovascular Risk and Hepatocellular Carcinoma in NAFLD Patients. <i>Cancers</i> , 2021 , 13,	6.6	6
140	Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	8
139	Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	9
138	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. <i>Journal of Hepatology</i> , 2021 , 74, 775-782	13.4	50
137	PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD. <i>Liver International</i> , 2021 , 41, 321-332	7.9	10
136	NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease. <i>Liver International</i> , 2021 , 41, 2712-2719	7.9	3
135	Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD. <i>Journal of Hepatology</i> , 2021 , 75, 506-513	13.4	8

134	Genetics Is of the Essence to Face NAFLD. <i>Biomedicines</i> , 2021 , 9,	4.8	7
133	From Environment to Genome and Back: A Lesson from Mutations. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	5
132	Genetic variants in the MTHFR are not associated with fatty liver disease. <i>Liver International</i> , 2020 , 40, 1934-1940	7.9	1
131	Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes. <i>EBioMedicine</i> , 2020 , 52, 102658	8.8	36
130	Nutrition and Genetics in NAFLD: The Perfect Binomium. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	26
129	Dysmetabolic Hyperferritinemia and Dysmetabolic Iron Overload Syndrome (DIOS): Two Related Conditions or Different Entities?. <i>Current Pharmaceutical Design</i> , 2020 , 26, 1025-1035	3.3	7
128	Genetic and metabolic factors: the perfect combination to treat metabolic associated fatty liver disease. <i>Exploration of Medicine</i> , 2020 , 1, 218-243	1.1	3
127	Impact of natural neuromedin-B receptor variants on iron metabolism. <i>American Journal of Hematology</i> , 2020 , 95, 167-177	7.1	2
126	Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis. <i>Cell Metabolism</i> , 2020 , 31, 406-421.e7	24.6	69
125	Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2020 , 1865, 158765	5	4
124	MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD. <i>EBioMedicine</i> , 2020 , 57, 102866	8.8	17
123	Leptin, Resistin, and Proprotein Convertase Subtilisin/Kexin Type 9: The Role of STAT3. <i>American Journal of Pathology</i> , 2020 , 190, 2226-2236	5.8	12
122	FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 517-519	6.9	8
121	FKlotho gene variation is associated with liver damage in children with NAFLD. <i>Journal of Hepatology</i> , 2020 , 72, 411-419	13.4	27
120	Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker. <i>Gut</i> , 2020 , 69, 1855-1866	19.2	34
119	Lipid accumulation impairs lysosomal acid lipase activity in hepatocytes: Evidence in NAFLD patients and cell cultures. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2019 , 1864, 158523	5	12
118	Alcohol or Gut Microbiota: Who Is the Guilty?. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	59
117	Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity. <i>Liver International</i> , 2019 , 39, 1742-1754	7.9	37

116	gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. <i>Journal of Lipid Research</i> , 2019 , 60, 1144-1153	6.3	27
115	Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2019 , 9, 3682	4.9	42
114	Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2310-2319.e6	6.9	42
113	The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids. <i>Scientific Reports</i> , 2019 , 9, 11585	4.9	44
112	mir-101-3p Downregulation Promotes Fibrogenesis by Facilitating Hepatic Stellate Cell Transdifferentiation During Insulin Resistance. <i>Nutrients</i> , 2019 , 11,	6.7	19
111	The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies. <i>Nutrients</i> , 2019 , 11,	6.7	42
110	Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. <i>Journal of Internal Medicine</i> , 2018 , 283, 356-370	10.8	140
109	Hepatic iron is the major determinant of serum ferritin in NAFLD patients. <i>Liver International</i> , 2018 , 38, 164-173	7.9	38
108	Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	85
107	miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	70
106	Genetic and Epigenetic Modifiers of Alcoholic Liver Disease. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	44
105	FGF23 and Fetuin-A Interaction in the Liver and in the Circulation. <i>International Journal of Biological Sciences</i> , 2018 , 14, 586-598	11.2	9
104	Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease. <i>Hepatology Communications</i> , 2018 , 2, 666-675	6	30
103	Rare ceruloplasmin variants are associated with hyperferritinemia and increased hepatic iron in NAFLD patients: results from a NGS study. <i>Journal of Hepatology</i> , 2018 , 68, S58-S59	13.4	3
102	Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease. <i>Clinical Science</i> , 2017 , 131, 1301-1315	6.5	38
101	Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 2660-2669	5.6	30
100	Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1604-1611.e1	6.9	83
99	Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis. <i>Gastroenterology</i> , 2017 , 153, 1568-1580.e10	13.3	13

98	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. <i>Cancer Medicine</i> , 2017 , 6, 1930-1940	4.8	29
97	Interferon lambda 4 rs368234815 TT>G variant is associated with liver damage in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2017 , 66, 1885-1893	11.2	59
96	Iron overload induces hypogonadism in male mice via extrahypothalamic mechanisms. <i>Molecular and Cellular Endocrinology</i> , 2017 , 454, 135-145	4.4	8
95	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. <i>Scientific Reports</i> , 2017 , 7, 4492	4.9	131
94	GNPAT p.D519G variant and iron metabolism during oral iron tolerance test. <i>Hepatology</i> , 2017 , 65, 384-385	3.5	3
93	A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	39
92	PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis. <i>Human Molecular Genetics</i> , 2016 , 25, 5212-5222	5.6	71
91	MBOAT7 locus rs641738 variant predisposes to hepatocellular carcinoma in nonalcoholic fatty liver. <i>Digestive and Liver Disease</i> , 2016 , 48, e7-e8	3.3	2
90	Reply to "Statin treatment for non-alcoholic steatohepatitis". <i>Journal of Hepatology</i> , 2016 , 64, 242-3	13.4	
89	Hepcidin resistance in dysmetabolic iron overload. <i>Liver International</i> , 2016 , 36, 1540-8	7.9	22
88	The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development--a potential therapeutic target?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016 , 10, 229-42	4.2	32
87	MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2016 , 64, 682-90	13.4	79
86	The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. <i>Gastroenterology</i> , 2016 , 150, 1219-1230.e6	13.3	347
85	Genetics of nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2016 , 65, 1026-37	12.7	67
84	Nutritional therapy for nonalcoholic fatty liver disease. <i>Journal of Nutritional Biochemistry</i> , 2016 , 29, 1-11	6.3	72
83	Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2016 , 11, e0162473	3.7	34
82	Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2016 , 11, e0163069	3.7	45
81	The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage. <i>Hepatology</i> , 2016 , 63, 787-98	11.2	70

80	Liver fat accumulation is associated with circulating PCSK9. <i>Annals of Medicine</i> , 2016 , 48, 384-91	1.5	78
79	Particulate matter phagocytosis induces tissue factor in differentiating macrophages. <i>Journal of Applied Toxicology</i> , 2016 , 36, 151-60	4.1	6
78	Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. <i>Hepatology</i> , 2015 , 61, 506-14	11.2	311
77	The UCP2 -866G>A promoter region polymorphism is associated with nonalcoholic steatohepatitis. <i>Liver International</i> , 2015 , 35, 1574-80	7.9	35
76	PNPLA3 I148M Variant Influences Circulating Retinol in Adults with Nonalcoholic Fatty Liver Disease or Obesity. <i>Journal of Nutrition</i> , 2015 , 145, 1687-91	4.1	59
75	Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. <i>Hepatology</i> , 2015 , 62, 111-7	11.2	46
74	Increased circulating adiponectin in males with chronic HCV hepatitis. <i>European Journal of Internal Medicine</i> , 2015 , 26, 635-9	3.9	5
73	High fat diet subverts hepatocellular iron uptake determining dysmetabolic iron overload. <i>PLoS ONE</i> , 2015 , 10, e0116855	3.7	30
72	Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis. <i>BioMed Research International</i> , 2015 , 2015, 460190	3	89
71	Statin use and non-alcoholic steatohepatitis in at risk individuals. <i>Journal of Hepatology</i> , 2015 , 63, 705-12	3.4	227
70	Reply: To PMID 25251399. <i>Hepatology</i> , 2015 , 62, 660	11.2	6
69	Iron Stores, Hcpidin, and Aortic Stiffness in Individuals with Hypertension. <i>PLoS ONE</i> , 2015 , 10, e0134635	3.7	21
68	Juvenile hemochromatosis associated with heterozygosity for novel hemojuvelin mutations and with unknown cofactors. <i>Annals of Hepatology</i> , 2014 , 13, 568-571	3.1	4
67	CDKN1A: a double-edged sword in fatty liver?. <i>Cell Cycle</i> , 2014 , 13, 1371-2	4.7	7
66	Hepatic steatosis and PNPLA3 I148M variant are associated with serum Fetuin-A independently of insulin resistance. <i>European Journal of Clinical Investigation</i> , 2014 , 44, 627-33	4.6	21
65	PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. <i>Human Molecular Genetics</i> , 2014 , 23, 4077-85	5.6	230
64	Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C. <i>PLoS ONE</i> , 2014 , 9, e106022	3.7	9
63	A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. <i>World Journal of Gastroenterology</i> , 2014 , 20, 3002-10	5.6	66

62	Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. <i>World Journal of Gastroenterology</i> , 2014 , 20, 12945-55	5.6	98
61	Juvenile hemochromatosis associated with heterozygosity for novel hemojuvelin mutations and with unknown cofactors. <i>Annals of Hepatology</i> , 2014 , 13, 568-71	3.1	1
60	Dietary iron overload induces visceral adipose tissue insulin resistance. <i>American Journal of Pathology</i> , 2013 , 182, 2254-63	5.8	101
59	The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis. <i>BMC Nephrology</i> , 2013 , 14, 48	2.7	17
58	Liver transplantation for hepatocellular carcinoma in a patient with a novel telomerase mutation and steatosis. <i>Journal of Hepatology</i> , 2013 , 58, 399-401	13.4	11
57	Increased insulin receptor substrate 2 expression is associated with steatohepatitis and altered lipid metabolism in obese subjects. <i>International Journal of Obesity</i> , 2013 , 37, 986-92	5.5	33
56	PNPLA3 I148M variant and hepatocellular carcinoma: a common genetic variant for a rare disease. <i>Digestive and Liver Disease</i> , 2013 , 45, 619-24	3.3	42
55	IL28B rs12979860 polymorphism influences serum TNFalpha levels in chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2013 , 45, 348-9	3.3	2
54	Peroxisome proliferator-activated receptor genetic polymorphisms and nonalcoholic Fatty liver disease: any role in disease susceptibility?. <i>PPAR Research</i> , 2013 , 2013, 452061	4.3	17
53	Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B. <i>Hepatology</i> , 2013 , 58, 1245-52	11.2	56
52	Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. <i>Current Pharmaceutical Design</i> , 2013 , 19, 5219-38	3.3	148
51	PNPLA3 I148M polymorphism, clinical presentation, and survival in patients with hepatocellular carcinoma. <i>PLoS ONE</i> , 2013 , 8, e75982	3.7	36
50	PNPLA3 I148M polymorphism and progressive liver disease. <i>World Journal of Gastroenterology</i> , 2013 , 19, 6969-78	5.6	153
49	A novel alpha1-antitrypsin null variant (PiQ0Milano). <i>World Journal of Hepatology</i> , 2013 , 5, 458-61	3.4	7
48	Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 1434-42	6.1	32
47	T-ARMS-PCR for the evaluation of rs12979860 IL28B genotype: an optimized protocol. <i>Journal of Viral Hepatitis</i> , 2012 , 19, 228-228	3.4	2
46	Effect of the A736V TMPRSS6 polymorphism on the penetrance and clinical expression of hereditary hemochromatosis. <i>Journal of Hepatology</i> , 2012 , 57, 1319-25	13.4	27
45	The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. <i>Journal of Hepatology</i> , 2012 , 56, 448-54	13.4	126

44	The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls. <i>BMC Gastroenterology</i> , 2012 , 12, 111	3	50
43	The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease. <i>PLoS ONE</i> , 2012 , 7, e48804	3.7	37
42	LPIN1 rs13412852 polymorphism in pediatric nonalcoholic fatty liver disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2012 , 54, 588-93	2.8	46
41	Patatin-like phospholipase domain containing-3 gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis. <i>World Journal of Gastroenterology</i> , 2012 , 18, 2813-20	5.6	42
40	Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2012 , 18, 3782-6	5.6	31
39	The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. <i>Journal of Hepatology</i> , 2011 , 55, 1409-14	13.4	65
38	Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. <i>Journal of Hepatology</i> , 2011 , 55, 920-32	13.4	205
37	Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2011 , 21, 568-75	4.5	62
36	A tetra-primer amplification refractory mutation system polymerase chain reaction for the evaluation of rs12979860 IL28B genotype. <i>Journal of Viral Hepatitis</i> , 2011 , 18, 628-30	3.4	22
35	Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. <i>Hepatology</i> , 2011 , 53, 791-9	11.2	199
34	Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011 , 31, 683-90 ^{9.4}		67
33	Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. <i>Gut</i> , 2010 , 59, 267-73	19.2	117
32	A promoter polymorphism in the liver-specific fatty acid transport protein 5 is associated with features of the metabolic syndrome and steatosis. <i>Hormone and Metabolic Research</i> , 2010 , 42, 854-9	3.1	33
31	Serum hyaluronic acid for the screening of progressive nonalcoholic steatohepatitis in children: a promising approach. <i>Translational Research</i> , 2010 , 156, 226-8	11	2
30	HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. <i>Gastroenterology</i> , 2010 , 138, 905-12	13.3	203
29	Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2010 , 53, 927-33	13.4	51
28	Iron-dependent regulation of MDM2 influences p53 activity and hepatic carcinogenesis. <i>American Journal of Pathology</i> , 2010 , 176, 1006-17	5.8	54
27	Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010 , 51, 1209-17	11.2	445

26	I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010 , 52, 1274-80	11.2	200
25	Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study. <i>BMC Gastroenterology</i> , 2010 , 10, 102	3	46
24	HFE mutations modulate the effect of iron on serum hepcidin-25 in chronic hemodialysis patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009 , 4, 1331-7	6.9	24
23	Can nonalcoholic steatohepatitis trigger porphyria cutanea tarda clinical manifestations?. <i>Internal and Emergency Medicine</i> , 2009 , 4, 91-2	3.7	3
22	Ferroportin-1 in the recurrence of hepatic iron overload after liver transplantation. <i>Digestive and Liver Disease</i> , 2009 , 41, e17-20	3.3	3
21	Iron genes, dysmetabolism and fibrosis in chronic hepatitis C. <i>Journal of Hepatology</i> , 2008 , 48, 513-4; author reply 514-5	13.4	3
20	Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. <i>American Journal of Pathology</i> , 2008 , 172, 738-47	5.8	124
19	Bloodletting ameliorates insulin sensitivity and secretion in parallel to reducing liver iron in carriers of HFE gene mutations: response to Equitani et al. <i>Diabetes Care</i> , 2008 , 31, e18; author reply e19	14.6	8
18	Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis. <i>Diabetes</i> , 2008 , 57, 1355-62	0.9	128
17	HFE genotype influences erythropoiesis support requirement in hemodialysis patients: a prospective study. <i>American Journal of Nephrology</i> , 2008 , 28, 311-6	4.6	11
16	HFE mutations in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2008 , 47, 1794-5; author reply 1795-6	11.2	11
15	Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis. <i>Haematologica</i> , 2007 , 92, 1037-42	6.6	60
14	Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. <i>American Journal of Gastroenterology</i> , 2007 , 102, 1251-8	0.7	234
13	HFE gene mutations and oxidative stress influence serum ferritin, associated with vascular damage, in hemodialysis patients. <i>American Journal of Nephrology</i> , 2007 , 27, 101-7	4.6	19
12	Alpha 1-antitrypsin mutations in NAFLD: high prevalence and association with altered iron metabolism but not with liver damage. <i>Hepatology</i> , 2006 , 44, 857-64	11.2	74
11	TNFalpha genotype affects TNFalpha release, insulin sensitivity and the severity of liver disease in HCV chronic hepatitis. <i>Journal of Hepatology</i> , 2005 , 43, 944-50	13.4	32
10	Iron and insulin resistance. <i>Alimentary Pharmacology and Therapeutics</i> , 2005 , 22 Suppl 2, 61-3	6.1	60
9	TNFalpha promoter polymorphisms. <i>Methods in Molecular Medicine</i> , 2004 , 98, 47-58		8

8	The mitochondrial superoxide dismutase A16V polymorphism in the cardiomyopathy associated with hereditary haemochromatosis. <i>Journal of Medical Genetics</i> , 2004 , 41, 946-50	5.8	65
7	Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. <i>Digestive and Liver Disease</i> , 2003 , 35, 172-8	3.3	66
6	TNFalpha promoter polymorphisms in Italian patients with porphyria cutanea tarda. <i>Digestive and Liver Disease</i> , 2003 , 35, 596-7	3.3	1
5	What is the contribution of differences in three measures of tumor necrosis factor-alpha activity to insulin resistance in healthy volunteers?. <i>Metabolism: Clinical and Experimental</i> , 2003 , 52, 1593-6	12.7	10
4	Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. <i>Gastroenterology</i> , 2002 , 122, 274-80	13.3	253
3	TNF alpha polymorphisms, HFE gene mutations and acquired factors in Italian patients with porphyria cutanea tarda. <i>Journal of Hepatology</i> , 2002 , 36, 157-158	13.4	53
2	Tumor necrosis factor alpha promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis. <i>Blood</i> , 2001 , 97, 3707-12	2.2	80
1	Relationship between TNF-alpha and iron metabolism in differentiating human monocytic THP-1 cells. <i>British Journal of Haematology</i> , 2000 , 110, 978-84	4.5	47